CN118922406A - Kif18a抑制剂的合成 - Google Patents

Kif18a抑制剂的合成 Download PDF

Info

Publication number
CN118922406A
CN118922406A CN202380018655.9A CN202380018655A CN118922406A CN 118922406 A CN118922406 A CN 118922406A CN 202380018655 A CN202380018655 A CN 202380018655A CN 118922406 A CN118922406 A CN 118922406A
Authority
CN
China
Prior art keywords
compound
solvent
alkyl
benzyl
base
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202380018655.9A
Other languages
English (en)
Chinese (zh)
Inventor
S·卡耶
D·G·格林
M·T·科贝特
C·魏
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Amgen Inc
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of CN118922406A publication Critical patent/CN118922406A/zh
Pending legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C313/00Sulfinic acids; Sulfenic acids; Halides, esters or anhydrides thereof; Amides of sulfinic or sulfenic acids, i.e. compounds having singly-bound oxygen atoms of sulfinic or sulfenic groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C313/02Sulfinic acids; Derivatives thereof
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D211/00Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/10Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms
    • C07D211/14Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms with hydrocarbon or substituted hydrocarbon radicals attached to the ring nitrogen atom
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D221/00Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
    • C07D221/20Spiro-condensed ring systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F3/00Compounds containing elements of Groups 2 or 12 of the Periodic Table
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13Crystalline forms, e.g. polymorphs
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02PCLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00Technologies relating to chemical industry
    • Y02P20/50Improvements relating to the production of bulk chemicals
    • Y02P20/55Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Steroid Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Silver Salt Photography Or Processing Solution Therefor (AREA)
CN202380018655.9A 2022-01-26 2023-01-26 Kif18a抑制剂的合成 Pending CN118922406A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202263303470P 2022-01-26 2022-01-26
US63/303,470 2022-01-26
PCT/US2023/011636 WO2023146973A1 (en) 2022-01-26 2023-01-26 Synthesis of a kif18a inhibitor

Publications (1)

Publication Number Publication Date
CN118922406A true CN118922406A (zh) 2024-11-08

Family

ID=85328813

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202380018655.9A Pending CN118922406A (zh) 2022-01-26 2023-01-26 Kif18a抑制剂的合成

Country Status (12)

Country Link
US (1) US20250129050A1 (https=)
EP (1) EP4469437A1 (https=)
JP (1) JP2025505892A (https=)
KR (1) KR20240144140A (https=)
CN (1) CN118922406A (https=)
AR (1) AR128353A1 (https=)
AU (1) AU2023211589A1 (https=)
CA (1) CA3248925A1 (https=)
IL (1) IL314221A (https=)
MX (1) MX2024009163A (https=)
TW (1) TW202342451A (https=)
WO (1) WO2023146973A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115925589A (zh) * 2022-12-26 2023-04-07 诚达药业股份有限公司 一种脂肪族亚磺酸钙盐及其制备方法

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA54543A (fr) 2018-12-20 2022-03-30 Amgen Inc Inhibiteurs de kif18a
TW202416973A (zh) 2022-08-18 2024-05-01 美商雅客森醫療公司 Kif18a抑制劑及其用途
WO2025036479A1 (zh) * 2023-08-16 2025-02-20 上海湃隆生物科技有限公司 驱动蛋白kif18a抑制剂及其应用

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA54543A (fr) * 2018-12-20 2022-03-30 Amgen Inc Inhibiteurs de kif18a
MX2022012992A (es) * 2020-04-14 2022-11-08 Amgen Inc Inhibidores de kif18a para el tratamiento de enfermedades neoplasicas.

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115925589A (zh) * 2022-12-26 2023-04-07 诚达药业股份有限公司 一种脂肪族亚磺酸钙盐及其制备方法

Also Published As

Publication number Publication date
CA3248925A1 (en) 2023-08-03
JP2025505892A (ja) 2025-03-03
TW202342451A (zh) 2023-11-01
MX2024009163A (es) 2024-08-09
AR128353A1 (es) 2024-04-24
EP4469437A1 (en) 2024-12-04
WO2023146973A1 (en) 2023-08-03
IL314221A (en) 2024-09-01
KR20240144140A (ko) 2024-10-02
US20250129050A1 (en) 2025-04-24
AU2023211589A1 (en) 2024-07-25

Similar Documents

Publication Publication Date Title
CN118922406A (zh) Kif18a抑制剂的合成
TWI475992B (zh) 製備4-{4-[({[4-氯-3-(三氯甲基)-苯基]胺基}羰基)胺基]-3-氟苯氧基}-n-甲基吡啶-2-甲醯胺、其鹽及單水合物之方法
CN105658629B (zh) 用于制备pde4抑制剂的方法
JP7157752B2 (ja) Ag-10、その中間体及びその塩の調製方法
CN102143964A (zh) 制备腺嘌呤化合物的方法
EP3271018A1 (en) Processes and intermediates for the preparation of pimavanserin
JP2019527228A (ja) 新規化合物および方法
TW201625634A (zh) 科帕利普(copanlisib)及其二鹽酸鹽之合成
AU2020267299A1 (en) Methods of making protein deacetylase inhibitors
MXPA04008109A (es) Metodo para preparar cloruro de bencisoxasol metano sulfonilo y su amidacion para formar zonisamida.
RU2466983C2 (ru) Способ синтеза сульфонилгалогенидов и сульфонамидов из солей сульфоновых кислот
EA052216B1 (ru) Синтез ингибитора kif18a
JPH04364168A (ja) スルホンアミドピリジン化合物
WO2011036648A1 (en) Polymorphs of sorafenib acid addition salts
KR20140027921A (ko) 디(아릴아미노)아릴 화합물의 제조 방법 및 그 합성 중간체
TWI247735B (en) New process for the preparation of a biphenyl ether compound
CN121511241A (zh) 化合物的新制备方法及新结晶形式
HK1251233A1 (en) Method for producing dicarboxylic acid compound
HK40098884A (zh) Ag-10的制备方法、其中间体及其盐
JP2005537273A (ja) N−(1−メチルエチルアミノカルボニル)−4−(3−メチルフェニルアミノ)−3−ピリジンスルホンアミドの変態iの新規な製造方法
EA050035B1 (ru) Способы получения ag-10, его промежуточных соединений и их солей

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination